Guillaume L.
- Country
- France
- Department
- Médecine Interne Unité d'Immunologie Clinique
Research Overview
- Efficacy and Safety Evaluation of Benralizumab in Patients with Hypereosinophilic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
- Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating BP1.7881 Efficacy and Safety in Adult Eosinophilic Esophagitis Patients
Data & Insights
Has run more than one trial at 4 of 31 partner sites.
Specializations
Hypereosinophilic Disorders
This investigator specializes in treating Hypereosinophilic Syndrome (HES), a rare blood disorder characterized by elevated levels of eosinophils. Their research encompasses innovative therapeutic approaches using targeted biological treatments for managing this condition.
- HES Management
- Disease Flare Prevention
- Biological Therapy Applications
Autoimmune Vasculitis
The investigator focuses on treating Eosinophilic Granulomatosis with Polyangiitis (EGPA), particularly in its relapsing or refractory forms. Their work involves evaluating novel therapeutic options for patients who require advanced treatment approaches beyond standard care.
- Refractory EGPA Treatment
- Long-term Disease Management
- Alternative Treatment Pathways
Treatment Optimization
A key area of interest lies in developing glucocorticoid-sparing treatments for EGPA patients. The investigator works on establishing effective therapeutic regimens for both newly-diagnosed and relapsing cases, with particular attention to minimizing steroid dependency.
- Steroid Reduction Strategies
- Remission Induction
- Treatment Protocol Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.